Laboratories that wish to perform the analysis of doping controls for sports under the World Anti-Doping Code must achieve and maintain accreditation from WADA. The International Standard for Laboratories (ISL) and its related technical documents specify the criteria that must be met for accreditation and re-accreditation, as well as standards that must be met for the production of valid test results and evidentiary data.
To fully serve the development of the Athlete Biological Passport (ABP), particularly in regions where the current network of WADA-accredited laboratories may be limited, WADA has approved these laboratories to conduct blood analyses in support of the ABP.
WADA publishes, from time to time, specific technical requirements, addressing particular operational areas of the accredited laboratories, in a Technical Document.
The Technical Documents constitute level-2 elements of the World Anti-Doping Program, and therefore implementation of the technical recommendations described in them is mandatory and must occur by the effective date specified in the Technical Document.
Technical Documents supersede any previous publication on a similar topic, or if applicable, the International Standard for Laboratories (ISL). The document in effect is the Technical Document whose effective date most recently precedes that of sample receipt date by the laboratory.
Technical Documents In Effect
(in alphabetical order)
|Summary of modifications||Effective Date*|
|TD2019BAR||TD2019BAR - Summary of modifications||1 June 2019|
|TD2019CG/LH||TD2019CG/LH - Summary of modifications||1 Mar. 2019|
|TD2019DL Version 2||TD2019DL Version 2 - Summary of modifications||1 Sept. 2019|
|TD2018EAAS||TD2018EAAS - Summary of modifications||1 Sep. 2018|
|TD2014EPO||TD2014EPO - Summary of modifications||1 Sep. 2014|
|TD2019GH||TD2019GH - Summary of modifications||15 May 2019|
|TD2015IDCR||TD2015IDCR - Summary of modifications||1 Sep. 2015|
|TD2019IRMS||TD2019IRMS - Summary of modifications||1 Mar. 2019|
|TD2009LCOC||1 Jan. 2009|
|TD2019LDOC||4 Nov. 2019|
|TD2019MRPL||TD2019MRPL - Summary of modifications||15 May 2019|
|TD2019NA||TD2019NA - Summary of modifications||1 Mar. 2019|
|1 Mar. 2019|
* Deadline for implementation
WADA publishes Technical letters on an ad-hoc basis in order to provide instruction and guidance to the Laboratories, WADA-Approved Laboratories for the ABP and other stakeholders on particular issues related to the analysis, interpretation and reporting of results for specific Prohibited Substance(s) and/or Prohibited Method(s) or on the application of specific Laboratory procedures. Technical Letters are modified and/or withdrawn by WADA as deemed appropriate.
The Technical Letters constitute a WADA Laboratory standard document which supersedes any previous publication on a similar topic and becomes an integral part of the International Standard for Laboratories (ISL), and therefore the described technical recommendations are mandatory and shall be implemented as soon as possible after approval by the WADA Executive Committee and publishing on WADA’s website.
A Technical Letter shall be applied to samples which are received by the Laboratory on and after the Technical Letter’s effective date.
TECHNICAL LETTERS IN EFFECT
|Title||Document Number||Version Number||Effective Date|
|Meclofenoxate||TL01||2.0||24 March 2006|
|Mebeverine Metabolism||TL02||2.0||08 June 2012|
|Zilpaterol||TL03||2.0||04 December 2014|
|Zeranol||TL04||2.0||07 May 2015|
|Oxilofrine||TL05||2.0||07 May 2015|
|Possible Metabolism of Proguanil into Chlorazanil||TL06||2.0||27 January 2016|
|Andarine - Flutamide||TL07||2.0||17 August 2016|
|Use of Internal Standards||TL08||4.0||18 January 2017|
|Oxethazaine||TL09||2.0||16 February 2017|
|In situ Formation of Exogenous Compounds||TL10||2.0||12 April 2017|
|Oxymorphone||TL11||2.0||21 December 2017|
|Ostarine||TL12||2.0||31 January 2018|
|Trimetazidine||TL13||2.0||31 January 2018|
|Difference in “A” and “B” Sample Urine Characteristics||TL14||2.0||06 March 2018|
|Hydromorphone||TL15||2.0||06 March 2018|
|Tretoquinol||TL16||2.0||20 December 2018|
|Detection of Tulobuterol in the presence of Bupropion||TL17||2.0||16 April 2019|
|Testolactone||TL18||1.0||23 September 2019|
|Prednisone and Prednisolone||TL19||2.0||23 September 2019|
|Specific substances with a steroid structure||TL20||1.0||23 September 2019|
4 November 2019
In cooperation with WADA, the International Anti-Doping Agreement (IADA) has also developed guidelines for Anti-Doping Organizations that have already obtained an ISO certification or that wish to be ISO-certified. These are: Guidelines for Transition and Guidelines for Certification.
As with all guidelines under the World Anti-Doping Program, these documents are subject to ongoing review and reassessment.
WADA encourages feedback on the content of the Guidelines, and recommends that stakeholders always consult this Web site for the latest version.
Laboratory Guidelines currently in force:
- Human Growth Hormone (hGH) Biomarkers Test
- TUE enquiries by Accredited Laboratories
- Conducting and Reporting Subcontracted Analysis and Further Analysis for Doping Control
LABORATORY TESTING FIGURES
In accordance with Article 14.5 of the World Anti-Doping Code (the Code), WADA, acting as a central clearinghouse for Doping Control data, annually publishes statistical reports as reported by the WADA accredited laboratories in the Anti-Doping Administration and Management System (ADAMS).
The latest WADA Anti-Doping Testing Figures Report can be accessed here.
For a more complete overview of the Testing Figures, please consult the comprehensive Questions and Answers document.
Collaboration between WADA and the International Laboratory Accreditation Cooperation (ILAC) provides an important opportunity to conduct the International Standard for Laboratories (ISL) assessment concurrently with the ISO/IEC 17025 assessment for the WADA accredited anti-doping laboratories.
The List of ISL Assessors contains the names of the assessors from ILAC-member accreditation bodies trained by WADA for
the ISL assessment.